court-istock-451264349-tomloel-

tomloel / iStockphoto.com

3 April 2017Americas

Four of Acorda’s Ampyra patents invalidated

A Delaware district court has invalidated four patents owned by Acorda Therapeutics after the company and Alkermes Pharma Ireland alleged that Apotex, Mylan, Roxane Laboratories and Teva infringed them.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

BIO and PhRMA back Acorda in patent appeal

17 August 2017 The Biotechnology Industry Organization and the Pharmaceutical Research and Manufacturers of America, two trade groups representing US pharmaceutical companies, have backed Acorda in an appeal to the US Court of Appeals for the Federal Circuit.

Victory for Mylan and Teva as appeals court affirms invalidations

12 September 2018 Generic drug makers Mylan and Teva were afforded victory earlier this week when the US Court of Appeals for the Federal Circuit affirmed the invalidation of four patents owned by biotech company Acorda Therapeutics.

More on this story

BIO and PhRMA back Acorda in patent appeal

17 August 2017 The Biotechnology Industry Organization and the Pharmaceutical Research and Manufacturers of America, two trade groups representing US pharmaceutical companies, have backed Acorda in an appeal to the US Court of Appeals for the Federal Circuit.

Victory for Mylan and Teva as appeals court affirms invalidations

12 September 2018 Generic drug makers Mylan and Teva were afforded victory earlier this week when the US Court of Appeals for the Federal Circuit affirmed the invalidation of four patents owned by biotech company Acorda Therapeutics.

More on this story

BIO and PhRMA back Acorda in patent appeal

17 August 2017 The Biotechnology Industry Organization and the Pharmaceutical Research and Manufacturers of America, two trade groups representing US pharmaceutical companies, have backed Acorda in an appeal to the US Court of Appeals for the Federal Circuit.

Victory for Mylan and Teva as appeals court affirms invalidations

12 September 2018 Generic drug makers Mylan and Teva were afforded victory earlier this week when the US Court of Appeals for the Federal Circuit affirmed the invalidation of four patents owned by biotech company Acorda Therapeutics.

More features

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent